DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
Sulfatinib is an investigational drug.
There have been 11 clinical trials for Sulfatinib. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2015.
The most common disease conditions in clinical trials are Neuroendocrine Tumors, Carcinoid Tumor, and Biliary Tract Neoplasms. The leading clinical trial sponsors are Hutchison Medipharma Limited, Peking University, and [disabled in preview].
There are two US patents protecting this investigational drug and nineteen international patents.
Recent Clinical Trials for Sulfatinib
|A Phase IIb/III Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients||Hutchison Medipharma Limited||Phase 2/Phase 3|
|Trial of Sulfatinib Combined With JS001 in the Treatment of Advanced Solid Tumors||Peking University||Phase 1|
|To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers||Hutchison Medipharma Limited||Phase 1|
Top disease conditions for Sulfatinib
Top clinical trial sponsors for Sulfatinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Sulfatinib||Start Trial||Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use||Hutchison MediPharma Limited (Shanghai, CN)||Start Trial|
|Sulfatinib||Start Trial||Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use||Hutchison Medipharma Limited (Shanghai, CN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|